CLINUVEL announced an expansion of its VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore. This five-year investment solidifies the site’s transition into a global hub for developing advanced, long-acting peptide formulations.

Supported by the Singapore Economic Development Board (EDB), the enhanced facility will integrate comprehensive formulation and analytical sciences, focusing on advancing liquid controlled-release drug products designed to optimise therapeutic outcomes for patients. This expansion is a key pillar in CLINUVEL’s strategy of vertical integration and innovation in peptide-based medicine.

The VALLAURIX RD&I Centre is dedicated to creating novel pharmaceutical formulations that act as versatile platforms for delivering CLINUVEL’s melanocortins and other therapeutic peptides, with a focus on advanced stage programmes.

Since its founding in 2014, the VALLAURIX site has evolved, with the current ISO9001-certified centre opening in 2020 and receiving extensive upgrades in 2022. The new expansion will further broaden its formulation and analytical capabilities, with full commissioning and certification targeted for FY2028.

 “CLINUVEL has made a long-term investment in the VALLAURIX team and facility, which has resulted in important advancements in novel drug delivery systems. Our pipeline now includes platforms designed to optimise therapeutic dosing - delivering minimal, yet highly effective, levels of peptide in flexible formulations to better meet patient needs,” said Dr Dennis Wright, Chief Scientific Officer, CLINUVEL.

The expansion process will ensure that ongoing projects in novel pharmaceutical and PhotoCosmetic formulation continue uninterrupted. Simultaneously, it prepares CLINUVEL to translate its research into tangible advanced therapies.

“We are grateful for the support from EDB and are committed to building a truly unique, bespoke facility in Singapore. This positions CLINUVEL at the forefront of peptide delivery technologies, enabling us to execute our vision with speed and precision, said Lachlan Hay, Chief Operating Officer, CLINUVEL.

CLINUVEL’s global team is spearheading the expansion, with plans to gradually increase specialist headcount in Singapore over the next five years. This growth is made possible through a strengthened economic partnership with the EDB, whose continued investment facilitates the addition of technical expertise and state-of-the-art capabilities.

“This strategic expansion underscores CLINUVEL’s commitment to leveraging Singapore’s vibrant biotech ecosystem to address complex therapeutic challenges and deliver the next wave of peptide-based medicines,” Hay said.